{"id":"https://openalex.org/W7225012933","doi":"https://doi.org/10.2147/ott.s653346","title":"Early Treatment Failure in Real-World Bispecific-Antibody Therapy for Relapsed or Refractory Multiple Myeloma: Pathways, Determinants, and Measurement Gaps","display_name":"Early Treatment Failure in Real-World Bispecific-Antibody Therapy for Relapsed or Refractory Multiple Myeloma: Pathways, Determinants, and Measurement Gaps","publication_year":2026,"publication_date":"2026-10-31","ids":{"openalex":"https://openalex.org/W7225012933","doi":"https://doi.org/10.2147/ott.s653346"},"language":"en","primary_location":{"id":"doi:10.2147/ott.s653346","doi":"https://doi.org/10.2147/ott.s653346","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s653346","pdf_url":"https://www.dovepress.com/article/download/121657","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/article/download/121657","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100406577","display_name":"Qi Qi","orcid":"https://orcid.org/0009-0005-5107-7168","observed_orcids":["https://orcid.org/0009-0005-5107-7168","https://orcid.org/0000-0003-0028-3381","https://orcid.org/0000-0002-2530-9464"]},"institutions":[{"id":"https://openalex.org/I4210140515","display_name":"First Hospital of China Medical University","ror":"https://ror.org/04wjghj95","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210140515"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Qi Qi","raw_affiliation_strings":["Department of Hematology, The First Hospital of China Medical University, Shenyang, 110001, People\u2019s Republic of China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, The First Hospital of China Medical University, Shenyang, 110001, People\u2019s Republic of China;","institution_ids":["https://openalex.org/I4210140515"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047020466","display_name":"Bing Han","orcid":"https://orcid.org/0000-0003-3447-0513","observed_orcids":["https://orcid.org/0000-0003-3447-0513"]},"institutions":[{"id":"https://openalex.org/I4210140515","display_name":"First Hospital of China Medical University","ror":"https://ror.org/04wjghj95","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210140515"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Bing Han","raw_affiliation_strings":["Department of Oncology Medicine, The First Hospital of China Medical University, Shenyang, 110001, People\u2019s Republic of China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology Medicine, The First Hospital of China Medical University, Shenyang, 110001, People\u2019s Republic of China","institution_ids":["https://openalex.org/I4210140515"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5160273755","display_name":"Runshi Fu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140515","display_name":"First Hospital of China Medical University","ror":"https://ror.org/04wjghj95","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210140515"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Runshi Fu","raw_affiliation_strings":["Department of Hematology, The First Hospital of China Medical University, Shenyang, 110001, People\u2019s Republic of China;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, The First Hospital of China Medical University, Shenyang, 110001, People\u2019s Republic of China;","institution_ids":["https://openalex.org/I4210140515"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210140515"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.86484811,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"Volume 19","issue":null,"first_page":"1","last_page":"18"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9729999899864197},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.984000027179718},{"id":"https://openalex.org/keywords/b-cell-maturation-antigen","display_name":"BCMA","score":0.7459999918937683},{"id":"https://openalex.org/keywords/gprc5d","display_name":"GPRC5D","score":0.9750000238418579},{"id":"https://openalex.org/keywords/early-treatment-failure","display_name":"early treatment failure","score":0.8899999856948853},{"id":"https://openalex.org/keywords/early-mortality","display_name":"early mortality","score":0.8209999799728394},{"id":"https://openalex.org/keywords/treatment-exposure","display_name":"treatment exposure","score":0.49399998784065247},{"id":"https://openalex.org/keywords/treatment-continuity","display_name":"treatment continuity","score":0.5600000023841858},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.5389999747276306},{"id":"https://openalex.org/keywords/treatment-delivery","display_name":"treatment delivery","score":0.3330000042915344},{"id":"https://openalex.org/keywords/infection","display_name":"infection","score":0.4180000126361847},{"id":"https://openalex.org/keywords/residual-tumor-burden","display_name":"residual tumor burden","score":0.6000000238418579},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.6370000243186951},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.8970000147819519}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.911899983882904},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.6635000109672546},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6008999943733215},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5216000080108643},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5126000046730042},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.46880000829696655},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.44670000672340393},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4440000057220459},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4171000123023987},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.39910000562667847},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.39660000801086426},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3785000145435333},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3450999855995178},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3343999981880188},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.30469998717308044},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.3034000098705292},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.2976999878883362},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.2824999988079071},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2766000032424927},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.26589998602867126},{"id":"https://openalex.org/C2987315675","wikidata":"https://www.wikidata.org/wiki/Q1773974","display_name":"Disease control","level":2,"score":0.26100000739097595},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.2515999972820282},{"id":"https://openalex.org/C40423286","wikidata":"https://www.wikidata.org/wiki/Q284172","display_name":"Selection bias","level":2,"score":0.25099998712539673}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.2147/ott.s653346","doi":"https://doi.org/10.2147/ott.s653346","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s653346","pdf_url":"https://www.dovepress.com/article/download/121657","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:dovepress.com/121657","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/early-treatment-failure-in-real-world-bispecific-antibody-therapy-for--peer-reviewed-fulltext-article-OTT","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Review"}],"best_oa_location":{"id":"doi:10.2147/ott.s653346","doi":"https://doi.org/10.2147/ott.s653346","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ott.s653346","pdf_url":"https://www.dovepress.com/article/download/121657","source":{"id":"https://openalex.org/S120324992","display_name":"OncoTargets and Therapy","issn_l":"1178-6930","issn":["1178-6930"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"OncoTargets and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225012933.pdf","grobid_xml":"https://content.openalex.org/works/W7225012933.grobid-xml"},"referenced_works_count":65,"referenced_works":["https://openalex.org/W2048483323","https://openalex.org/W2078808624","https://openalex.org/W2291203170","https://openalex.org/W2404984931","https://openalex.org/W2486629951","https://openalex.org/W3098371200","https://openalex.org/W3127802833","https://openalex.org/W3158660900","https://openalex.org/W4239330499","https://openalex.org/W4282033105","https://openalex.org/W4293356848","https://openalex.org/W4308045507","https://openalex.org/W4312072518","https://openalex.org/W4323811721","https://openalex.org/W4361290448","https://openalex.org/W4379769608","https://openalex.org/W4384664890","https://openalex.org/W4385456897","https://openalex.org/W4385839624","https://openalex.org/W4386272219","https://openalex.org/W4386324983","https://openalex.org/W4387128075","https://openalex.org/W4387934161","https://openalex.org/W4391052632","https://openalex.org/W4392360934","https://openalex.org/W4395068649","https://openalex.org/W4396515091","https://openalex.org/W4396789596","https://openalex.org/W4398197010","https://openalex.org/W4399242496","https://openalex.org/W4399716637","https://openalex.org/W4400763625","https://openalex.org/W4402836453","https://openalex.org/W4405013158","https://openalex.org/W4405623021","https://openalex.org/W4406159439","https://openalex.org/W4408392330","https://openalex.org/W4408660014","https://openalex.org/W4409051942","https://openalex.org/W4409147719","https://openalex.org/W4409249692","https://openalex.org/W4409721146","https://openalex.org/W4410229940","https://openalex.org/W4411654144","https://openalex.org/W4411874835","https://openalex.org/W4412123441","https://openalex.org/W4412767113","https://openalex.org/W4413273659","https://openalex.org/W4415072419","https://openalex.org/W4415995326","https://openalex.org/W4416573220","https://openalex.org/W4416780523","https://openalex.org/W4416981448","https://openalex.org/W4417156840","https://openalex.org/W7118130287","https://openalex.org/W7118530433","https://openalex.org/W7130517817","https://openalex.org/W7131302622","https://openalex.org/W7133764957","https://openalex.org/W7134969309","https://openalex.org/W7140843002","https://openalex.org/W7141266674","https://openalex.org/W7162767729","https://openalex.org/W7164411130","https://openalex.org/W7168981654"],"related_works":["https://openalex.org/W4414304158","https://openalex.org/W4417012998","https://openalex.org/W3214314910","https://openalex.org/W7204156306","https://openalex.org/W3195221202","https://openalex.org/W7167597930","https://openalex.org/W7204729881","https://openalex.org/W4402836453","https://openalex.org/W7131302622","https://openalex.org/W4403312974"],"abstract_inverted_index":{"Abstract:":[0],"T-cell\u2013redirecting":[1],"bispecific":[2,210,246],"antibodies":[3,211],"have":[4],"substantial":[5,79],"antimyeloma":[6],"activity":[7],"in":[8,17,93,115,133],"relapsed":[9],"or":[10],"refractory":[11],"multiple":[12,244],"myeloma,":[13,245],"but":[14],"their":[15],"effectiveness":[16],"routine":[18],"practice":[19],"depends":[20],"on":[21],"patients":[22,96],"reaching":[23],"treatment":[24,71,121,139,224,251,257,261],"and":[25,47,63,110,124,129,138,148,158,167,178,195,201,229,240],"maintaining":[26],"exposure":[27],"long":[28],"enough":[29],"to":[30,66,73,106,135],"achieve":[31],"disease":[32,108,136],"control.":[33],"Clinical":[34],"deterioration":[35],"before":[36,44],"dosing,":[37,40],"incomplete":[38],"step-up":[39],"interrupted":[41],"exposure,":[42,177,237],"progression":[43],"response,":[45,198],"infection,":[46],"early":[48,80,250,253],"death":[49],"can":[50,226],"limit":[51],"benefit.":[52,75],"This":[53],"narrative":[54],"review":[55],"integrates":[56],"clinical":[57,193],"trials,":[58],"commercial":[59],"cohorts,":[60],"translational":[61],"studies,":[62],"treatment-delivery":[64,241],"evidence":[65],"examine":[67],"these":[68],"failures":[69],"from":[70,97,182,216],"selection":[72],"durable":[74],"Commercial":[76],"cohorts":[77,219],"show":[78],"post-initiation":[81],"mortality,":[82,254],"predominantly":[83],"associated":[84],"with":[85,191],"progressive":[86],"myeloma.":[87],"Drug-specific":[88],"observations":[89],"distinguish":[90,179],"delayed":[91],"response":[92,150,228,259],"clinically":[94],"stable":[95],"established":[98],"progression,":[99],"relate":[100],"residual":[101],"tumor":[102],"burden":[103],"after":[104],"cytoreduction":[105],"subsequent":[107],"control,":[109],"place":[111],"prior":[112],"BCMA-directed":[113],"therapy":[114],"the":[116,119,192],"context":[117],"of":[118],"preceding":[120],"course.":[122],"Host":[123],"marrow":[125],"reserve,":[126],"immune":[127],"fitness,":[128],"infection":[130],"are":[131],"examined":[132],"relation":[134],"control":[137],"continuity.":[140],"Current":[141],"studies":[142],"commonly":[143],"begin":[144],"at":[145],"first":[146],"administration":[147],"report":[149],"among":[151],"evaluable":[152],"patients,":[153],"incompletely":[154],"capturing":[155],"pre-initiation":[156],"loss":[157],"reasons":[159,171],"for":[160,172,197],"non-evaluability.":[161],"Future":[162],"datasets":[163],"should":[164,187],"link":[165],"treatment-intended":[166],"treatment-initiated":[168],"populations,":[169],"retain":[170],"missed":[173],"transitions,":[174],"record":[175],"actual":[176],"unplanned":[180],"interruption":[181],"response-adapted":[183],"dose":[184,202],"modification.":[185],"Analyses":[186],"align":[188],"time":[189],"origin":[190],"question":[194],"account":[196],"supportive":[199],"interventions,":[200],"modification":[203],"as":[204],"time-dependent":[205],"variables":[206],"when":[207],"appropriate.":[208],"As":[209],"move":[212],"earlier,":[213],"prognostic":[214],"associations":[215],"heavily":[217],"pretreated":[218],"require":[220],"reassessment.":[221],"Reporting":[222],"across":[223],"stages":[225],"complement":[227],"survival":[230],"endpoints":[231],"by":[232],"distinguishing":[233],"aggressive":[234],"disease,":[235],"insufficient":[236],"competing":[238],"morbidity,":[239],"constraints.":[242],"Keywords:":[243],"antibodies,":[247],"BCMA,":[248],"GPRC5D,":[249],"failure,":[252],"real-world":[255],"evidence,":[256],"delivery,":[258],"evaluability,":[260],"continuity":[262]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-11-01T00:00:00"}